Post-COVID-19 multisystem inflammatory syndrome in children: a case report

• Autor(a) principal: Martins, Tauane Rene
• Data de Publicação: 2022
• Outros Autores: Leite, Gabriella Cavalcante, Hauy, Beatriz Nomada, Marconato, Gabrielle Gomides, Viana, Kamila Cristina, Modaelli, Jaqueline, Marqui, Náthalie Angélica Cardoso, Lima, Marina Lucca de Campos, Baptista, Rafaela de Fátima Ferreira, Righetti, Rawene Elza Veronesi Gonçalves, Mendes, Airton José
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: International Journal of Nutrology (Online)
• Texto Completo: https://ijn.zotarellifilhoscientificworks.com/index.php/ijn/article/view/235
• topic: COVID-19; SARS-CoV-2; Systemic Inflammatory Syndrome; Pediatrics; Kawasaki disease

Objective: Report of a case of Multisystem Inflammatory Syndrome in Children (MIS-C) post-COVID 19 and review of articles on the topic. Results: Coronavirus 2 (SARS-CoV-2) infection is a disease whose symptoms are similar between the adult and pediatric population, ranging from asymptomatic cases to more serious conditions that have spread global terror due to the high number of infections worldwide deaths. However, children have presented a milder clinic. It is worth mentioning, however, that this population is not completely risk-free, with reports of the association of the Coronavirus triggering inflammatory diseases, such as the so-called MIS-C whose complications can be as serious as the forms of symptoms experienced by adults. Conclusion: The temporal and serological relationship of a link with SARS-CoV-2 infection is supported by consistent data, however further studies are needed to establish SARS-CoV-2 as an inciting agent. Due to the severity of MIS-C, knowledge about this disease is necessary for a quick diagnosis and early treatment, aiming to reduce systemic lesions. Due to the increase in the number of cases of children affected by MIS-C, the use of immunomodulatory drugs, such as intravenous immunoglobulin (IVIG), aspirin, and systemic glucocorticoids, has been instituted as first-line therapy, to reduce inflammation and late complications.